Arformoterol Tartrate Solution
Product Images NDC 62332-633

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Arformoterol Tartrate (NDC 62332-633). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Arformoterol-1s-30-carton (Arformoterol 1s 30 Carton)

Arformoterol Tartrate Inhalation Solution 15 mcg per 2 mL carton by Alembic Pharmaceuticals Inc. The packaging contains 30 sterile unit-dose vials (2 mL each) for oral inhalation. It advises refrigeration or room temperature storage up to 6 weeks and is labeled for prescription use only. Manufactured by HOLOPACK in Germany.*

FDA Label Image

Arformoterol-1s-foil (Arformoterol 1s Foil)

Label for Arformoterol Tartrate Inhalation Solution 15 mcg/2 mL sterile unit-dose vial, indicated for respiratory inhalation. Label includes storage instructions, usage warnings, manufacturing details by Alembic Pharmaceuticals Inc. and HOLOPACK Verpackungstechnik GmbH, and notes it is for Rx only. Also contains NDC 62332-633 and barcode.*

FDA Label Image

Arformoterol 4s 15 Carton

Packaging label for Arformoterol Tartrate Inhalation Solution 15 mcg / 2 mL, a respiratory solution for oral inhalation. The label indicates the product comes in a box of 60 x 2 mL sterile unit dose vials (15 pouches with 4 unit dose vials each). It is labeled Rx only and manufactured by Alembic Pharmaceuticals Inc. Storage instructions include refrigeration or room temperature storage for up to 6 weeks.*

FDA Label Image

Arformoterol-4s-foil (Arformoterol 4s Foil)

Label for Arformoterol Tartrate inhalation solution, 15 mcg per 2 mL sterile unit-dose vials. The label includes dosage form, strength, handling instructions, storage conditions, and manufacturer details. Manufactured by HOLOPACK Verpackungstechnik GmbH and labeled for Alembic Pharmaceuticals Inc., Bedminster, NJ. The label is designed for four 2 mL sterile unit-dose vials.*

FDA Label Image

Arformoterol-fig1 (Arformoterol Fig1)

An instructional illustration showing a hand holding an Arformoterol tartrate inhalation device. The image demonstrates a user twisting or turning a part of the device, indicated by an arrow, likely to prepare the solution for inhalation.*

FDA Label Image

Arformoterol-fig2 (Arformoterol Fig2)

Illustration showing a hand inserting or placing a component into a device labeled 'RESERVOIR,' likely demonstrating assembly or use of a respiratory inhalation solution device.*

FDA Label Image

Arformoterol-fig3-4 (Arformoterol Fig3 4)

Illustrations depicting respiratory inhalation device components for Arformoterol tartrate solution, including a labeled mouthpiece and a labeled face mask. These figures likely demonstrate the parts used for administering the inhalation solution.*

FDA Label Image

Arformoterol-fig5 (Arformoterol Fig5)

A black and white instructional diagram showing a compressor device with a visible knob and a rectangular display or label area. A tubing is connected to the compressor, labeled "TUBING." The image is titled "Figure 5."*

FDA Label Image

Arformoterol-fig6 (Arformoterol Fig6)

Illustration showing the correct use of a respiratory inhalation device, demonstrating a person placing the mouthpiece in their mouth while holding the inhaler for administration of the medication.*

FDA Label Image

Arformoterol-graph1-new.jpg (Arformoterol Graph1 New)

A line graph depicting mean change from baseline FEV1 (liters) over 12 hours postdose. Two lines represent data for placebo and 15 mcg Arformoterol tartrate inhalation solution BID groups, showing lung function improvement over time.*

FDA Label Image

Arformoterol-graph2-new.jpg (Arformoterol Graph2 New)

A line graph showing the mean change from baseline FEV1 (L) over 12 hours postdose, comparing placebo and 15 mcg Arformoterol tartrate inhalation solution BID. The x-axis represents hours postdose, and the y-axis represents mean change in FEV1 in liters. The graph displays a significant increase in FEV1 for the Arformoterol group compared to placebo over time.*

FDA Label Image

Arformoterol-structure (Arformoterol Structure)

Chemical structure of arformoterol tartrate, showing the molecular components of the active ingredient with its molecular groups, including phenol, amine, and carboxyl groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.